ArticleJournal of cellular and molecular medicine2011

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.

Kevin R Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.